{
    "id": 25991,
    "fullName": "PDCD1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PDCD1 positive indicates the presence of the PDCD1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5133,
        "geneSymbol": "PDCD1",
        "terms": [
            "PDCD1",
            "CD279",
            "hPD-1",
            "hPD-l",
            "hSLE1",
            "PD-1",
            "PD1",
            "SLEB2"
        ]
    },
    "variant": "positive",
    "createDate": "01/24/2017",
    "updateDate": "08/01/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10837,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Libtayo (cemiplimab) reduced tumor growth and improved survival of knock-in mouse models expressing human PDCD1 (PD-1) that were engrafted with mouse colon carcinoma cells (PMID: 28265006).",
            "molecularProfile": {
                "id": 27130,
                "profileName": "PDCD1 positive"
            },
            "therapy": {
                "id": 5656,
                "therapyName": "Cemiplimab",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8864,
                    "pubMedId": 28265006,
                    "title": "Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28265006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17838,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, patients with an advanced solid tumor and PDCD1-expressing T cells treated with PF-06801591 demonstrated an overall objective response rate of 18.4% (7/38), with seven patients experiencing a partial response, and showed disease control in 21 patients (PMID: 31145415; NCT02573259).",
            "molecularProfile": {
                "id": 27130,
                "profileName": "PDCD1 positive"
            },
            "therapy": {
                "id": 7233,
                "therapyName": "PF-06801591",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15810,
                    "pubMedId": 31145415,
                    "title": "Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31145415"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14121,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, AEGN2034 demonstrated more than 59% saturation of PD-1 (PDCD1) occupancy on circulating effector cells in patients with advanced solid tumor, resulted in partial disease in 12% (3/25) and stable disease in 52% (13/25) of the patients (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3086-3086; NCT03104699).",
            "molecularProfile": {
                "id": 27130,
                "profileName": "PDCD1 positive"
            },
            "therapy": {
                "id": 5693,
                "therapyName": "AGEN2034",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11470,
                    "pubMedId": null,
                    "title": "Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.3086"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14968,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, advanced solid tumors expressing PDCD1 (PD1) in a humanized xenograft model had decreased tumor growth upon exposure to the CDC274 (PD-L1) antibody, LY3300054 (PMID: 29712568).",
            "molecularProfile": {
                "id": 27130,
                "profileName": "PDCD1 positive"
            },
            "therapy": {
                "id": 4368,
                "therapyName": "LY3300054",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11865,
                    "pubMedId": 29712568,
                    "title": "Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29712568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9833,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Gleevec (imatinib) and a PD-1 antibody resulted in a greater decrease in tumor weight and increased apoptotic activity in a gastrointestinal stromal tumor mouse model harboring KIT V558del (corresponds to human KIT V559del, PMID: 12754375) and expressing PD-1 compared to Gleevec (imatinib) and control (PMID: 27470968).",
            "molecularProfile": {
                "id": 27131,
                "profileName": "KIT V559del PDCD1 pos"
            },
            "therapy": {
                "id": 5249,
                "therapyName": "Imatinib + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7655,
                    "pubMedId": 12754375,
                    "title": "Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12754375"
                },
                {
                    "id": 7656,
                    "pubMedId": 27470968,
                    "title": "PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27470968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16015,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, treatment with Keytruda (pembrolizumab) (n=7) or an anti-PD-1/anti-CTLA4 combination therapy (n=1) resulted in responses in 50% (4/8; 1 complete response, 3 partial responses) of metastatic colorectal cancer patients with high microinstability or POLE mutations, and responses were associated with higher levels of CD8+ tumor infitrating lymphocytes (TILs), PD-1 expressing CD8+ TILs, and tumor-infiltrating T-cells with a Th1 phenotype (CD4+ Tbet+) (PMID: 29998005).",
            "molecularProfile": {
                "id": 31363,
                "profileName": "PDCD1 pos POLE mut"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14093,
                    "pubMedId": 29998005,
                    "title": "Immune profiling of microsatellite instability-high and polymerase \u03b5 (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29998005"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16016,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, treatment with Keytruda (pembrolizumab) (n=7) or an anti-PD-1/anti-CTLA4 combination therapy (n=1) resulted in responses in 50% (4/8; 1 complete response, 3 partial responses) of metastatic colorectal cancer patients with high microinstability or POLE mutations, and responses were associated with higher levels of CD8+ tumor infitrating lymphocytes (TILs), PD-1 expressing CD8+ TILs, and tumor-infiltrating T-cells with a Th1 phenotype (CD4+ Tbet+) (PMID: 29998005).",
            "molecularProfile": {
                "id": 31364,
                "profileName": "MSI high PDCD1 pos"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14093,
                    "pubMedId": 29998005,
                    "title": "Immune profiling of microsatellite instability-high and polymerase \u03b5 (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29998005"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17852,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Keytruda (pembrolizumab) treatment resulted in suppression of PDCD1 (PD-1)-positive T cells and expansion of clonal T cell populations that may target C-terminal mutant Calr in a patient with myelofibrosis harboring CALR L367Tfs*46 (PMID: 31266769; NCT02897765).",
            "molecularProfile": {
                "id": 32831,
                "profileName": "CALR L367Tfs*46 PDCD1 pos"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15822,
                    "pubMedId": 31266769,
                    "title": "Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31266769"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27130,
            "profileName": "PDCD1 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27131,
            "profileName": "KIT V559del PDCD1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31363,
            "profileName": "PDCD1 pos POLE mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31364,
            "profileName": "MSI high PDCD1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32831,
            "profileName": "CALR L367Tfs*46 PDCD1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}